CORO2B

Across TCGA pan-cancer cohorts, CORO2B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CORO2B data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CORO2B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CORO2B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, KIRP, and COAD are the cancer types where CORO2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	0.125	0.618	<.001	15	view →
KIRP	OS	Median	All	0.272	0.885	<.001	12	view →
COAD	OS	Median	All	0.342	0.875	<.001	6	view →
SKCM	DFS	Median	All	0.821	0.612	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CORO2B–STAD (DFS)

Open the STAD breakdown →